

The time is right for



MINOCIN I.V. 100 mg				
NDC #	UPC #		WAC Price	
14290-545-92	3 14290 5454 92 0		\$ 497.00	
CASE DIMENSIONS & WEIGHT				
Package Size (LxWxH)	Pack	Case Unit Size (LxWxH)	Weight (lbs)	Cube (cu ft)
4.5" x 1.7812" x 2.0625"	1	5-5/8" x 4-5/8" x 4-1/2"	2.13	0.185

Beginning Monday, March 1st, please note NEW Order Entry Numbers for Minocin® I.V. The NDC Number for Minocin® I.V. will remain the same: Triax NDC 14290-545-92

Wholesaler	NEW order entry Numbers	Wholesaler	NEW order entry Numbers
ABC	388-160	McKesson	1183300
Cardinal	4236006	HD Smith	227-0502
Morris & Dickson	014928		

For more information on Minocin I.V. or to place an order call 1-866-488-7429

For orders via Fax: 1888.556.7337 or visit www.minociniv.com

Important Risk Information

The most common adverse events associated with MINOCIN I.V. are nausea, vomiting, and diarrhea.

Central nervous system adverse events including light-headedness, dizziness, or vertigo have been reported with minocycline therapy, but are generally transient in nature. Other adverse events include tinnitus, headache, sedation, and skin pigmentation, particularly on the face and mucous membranes. MINOCIN I.V. is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines or to any of the components of the product formulation.

WARNING: MINOCIN I.V., like other tetracycline-class antibiotics, can cause fetal harm when administered to a pregnant woman. The use of drugs of the tetracycline class during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of teeth (yellow-gray-brown). Concurrent use of tetracyclines may render oral contraceptives less effective.

Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including MINOCIN I.V., and may range in severity from mild diarrhea to fatal colitis.

Please see Full Prescribing Information.

¹Waites, K.B., L.B. Duffy, and M.J. Dowzicky, *Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycolcycline antimicrobial*. Antimicrob Agents Chemother, 2006. **50**(10): p. 3479-84.

²Bouchillon, S.K., et al., *In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004)*. Diagn Microbiol Infect Dis, 2005. **52**(3): p. 173-9.

³Dowzicky, M.J., and C.H. Park, *Update on Antimicrobial Susceptibility Rates Among Gram-Negative and Gram-Positive Organisms in the United States: Results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007*. Clinical Therapeutics, 2008. **30**(11): p. 2040-2050.

⁴Draghi, D.C., et al., *Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance*. Chemotherapy, 2008. **54**(2): p. 91-100.

Manufactured for Triax Pharmaceuticals, LLC Cranford, NJ 07016 By Pantheon Italia S.p.A Monza (Milan), Italy

